Business Context and Reporting Period
Company: Apogee Therapeutics, Inc. (APGE)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Apogee is a clinical-stage biotechnology company developing novel biologics for inflammatory and immunology (I&I) indications, including atopic dermatitis (AD), asthma, and eosinophilic esophagitis (EoE). The company has no approved products and has not generated product revenue to date.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(159,965) | $(121,435) |
| Net Loss Per Share (Basic & Diluted) | $(2.20) | $(2.08) |
| Operating Expenses | $178,776 | $136,261 |
| Research & Development (R&D) | $128,120 | $102,090 |
| General & Administrative (G&A) | $46,295 | $34,171 |
| Merger Transaction Costs | $4,361 | $0 |
| Interest Income, Net | $20,548 | $14,981 |
| Interest Expense | $(1,580) | $0 |
| Cash Used in Operating Activities | $(126,950) | $(110,506) |
| Cash and Cash Equivalents (End of Period) | $105,571 | $124,486 |
| Total Marketable Securities | $1,188,298 | $771,373 |
| Revenue Share Liability | $99,231 | $0 |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose by $42.5 million (31%) year-over-year. R&D expenses increased by $26.0 million, primarily driven by the advancement of the zumilokibart (APG777) Phase 2 clinical trial and increased personnel/equity-based compensation. G&A expenses increased by $12.1 million due to higher headcount and equity compensation.
- Merger Transaction Costs: The company incurred $4.4 million in costs related to the pending merger with AbbVie, a new line item not present in the prior year.
- Revenue Share Liability: A new long-term liability of $99.2 million was recorded following a $100 million upfront payment from Blackstone Life Sciences (BXLS) under a Revenue Share Agreement in May 2026.
- Financing Activities: Net cash provided by financing activities was $518.2 million, compared to $1.8 million in the prior year. This was driven by $377.4 million from a March 2026 equity offering, $97.8 million from the Revenue Share Agreement, and $28.9 million from ATM sales.
- Investing Activities: Net cash used in investing activities was $417.2 million, primarily due to the purchase of $736.0 million in marketable securities, partially offset by maturities.
Guidance, Outlook, and Risks
Merger with AbbVie
On June 18, 2026, Apogee entered into a definitive agreement to be acquired by AbbVie Inc. for $135.11 per share in cash. The transaction is expected to close in the third quarter of 2026, subject to shareholder approval and regulatory clearances (including HSR Act expiration and German/Austrian clearance). If terminated under specific circumstances, Apogee may owe a termination fee of approximately $381.3 million.
Clinical Pipeline Updates
- Zumilokibart (APG777): Positive 52-week maintenance data from the APEX Phase 2 trial in AD was announced in March 2026. Positive 16-week induction data from Part B was announced in May 2026. Phase 3 trials (ADventure) are planned to initiate in the second half of 2026.
- APG279 (zumilokibart + APG990): Phase 1b head-to-head trial against DUPIXENT in AD is expected to read out in the second half of 2026.
- APG273 (zumilokibart + APG333): Plans for combination trials in asthma and COPD are expected to be announced in the second half of 2026.
Liquidity and Capital Resources
As of June 30, 2026, the company held $1.3 billion in cash, cash equivalents, and marketable securities. Management estimates these resources are sufficient to fund operations for at least the next 12 months. The company has no committed external funding sources beyond the contingent tranches of the Revenue Share Agreement.
Risks and Contingencies
- Merger Uncertainty: Failure to close the merger could result in significant disruption, loss of key personnel, and the need to raise additional capital on potentially unfavorable terms.
- Revenue Share Agreement: Future funding tranches ($100M, $200M, and up to $400M) are contingent on clinical milestones and regulatory approval. If the merger closes, a change of control payment or buy-back option may be triggered.
- Third-Party Reliance: The company relies on third-party manufacturers (WuXi Biologics, Samsung Biologics) and CROs. Geopolitical tensions and tariffs (e.g., on imports from China and South Korea) pose supply chain risks.
Investor Verification Checklist
- Merger Closing Conditions: Verify the status of remaining regulatory approvals (e.g., Australian ACCC) and shareholder vote outcomes to confirm the AbbVie acquisition will close in Q3 2026.
- Revenue Share Triggers: Confirm the specific clinical milestones required to unlock the remaining $700 million in potential funding from Blackstone Life Sciences.
- Phase 3 Initiation: Monitor the actual start date of the ADventure Phase 3 trials for zumilokibart, currently targeted for the second half of 2026.
- Termination Fee Exposure: Assess the company's ability to pay the $381.3 million termination fee if the merger fails, given the current cash position.
- Supply Chain Resilience: Evaluate the impact of potential U.S. tariffs on imports from South Korea (Samsung Biologics) and China (WuXi Biologics) on clinical trial timelines and costs.